GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
23 mai 2024 16h01 HE | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
27 nov. 2023 07h00 HE | Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
25 mai 2023 16h01 HE | Genelux Corporation
Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising...